A groundbreaking partnership between vaccine alliance Gavi and UNICEF is set to sharply reduce the cost of the R21/Matrix-M malaria vaccine, bringing new hope in the battle against one of the world’s deadliest childhood diseases. The new price is set at just $2.99 per dose—down a full 25% from previous rates—creating a path to protecting nearly seven million additional children by 2030.
In 2023, malaria accounted for an estimated 597,000 deaths. Most of these were children under five in Africa. The reduced vaccine cost directly translates into saved lives. It also leads to improved futures.
How Financing Innovation Unlocked Expanded Access
The agreement was made possible by an advance payment through the International Finance Facility for Immunisation (IFFIm), which uses long-term donor pledges to generate upfront funds.
This financial innovation allows rapid response to market opportunities and cuts barriers for low- and middle-income countries to access life-saving vaccines. By securing a lower price point, nations can now obtain more than 30 million extra doses over the next five years, yielding a potential $90 million in savings that can be reinvested into distribution and support.
Why the Deal Matters: Accelerating Malaria Immunisation
Demand for malaria vaccines is surging in Africa, with 24 countries now integrating the inoculation into routine child health programs. Last year alone, 14 countries introduced the vaccine for the first time, and seven followed in 2025. Overall, more than 40 million doses have already been distributed with Gavi support.
Gavi and UNICEF aim to fully vaccinate an additional 50 million children against malaria by 2030—a goal now within closer reach because of the new equitable pricing.
The Medical and Economic Value of Affordable Vaccines
Vaccines like R21/Matrix-M and RTS,S, both recommended by WHO, can reduce malaria cases by over half in the first year, with further protection after a booster dose. This not only saves lives—averaging a child death every minute in Africa—but also relieves struggling health systems by lowering hospital admissions and reducing treatment costs for families.
With each child needing four doses for full protection, the complete vaccination course is now more attainable. It costs about $12 per child. This is a fraction compared to traditional treatment costs or the expense of severe malaria care.
Partnerships and the Path Forward
The agreement shows the ongoing commitment of Gavi, UNICEF, and partners. They aim to build sustainable and competitive vaccine markets. They also support strong, country-led immunisation programs. At a time of reduced international aid, innovative deals like this ensure that families are not left behind. Every child receives a fair chance at protection. The expanded rollout promises to reshape public health. It will uplift communities. It also aims to eradicate malaria as a killer of young children in sub-Saharan Africa.
Q&A Section
Q: How much will the malaria vaccine cost under the new deal?
A: $2.99 per dose, a 25% reduction from previous pricing.
Q: How many additional children will benefit from the lower price?
A: Up to seven million children by 2030.
Q: What organizations were involved in securing this deal?
A: Gavi, UNICEF, IFFIm, and vaccine manufacturers like the Serum Institute of India.
Q: How effective are WHO-recommended malaria vaccines?
A: They cut malaria cases by more than half after the initial course and booster.
FAQ
Why is this pricing deal so important?
It makes the vaccine affordable for more countries, saving lives and improving health equity.
Where will the vaccines be distributed?
Primarily in Africa, but the deal could help other high-burden regions in the future.
How does innovative financing help?
It converts donor pledges into upfront cash, ensuring swift procurement and distribution.
What is the broader goal of Gavi and UNICEF?
To vaccinate 50 million additional children against malaria by 2030.
The Gavi-UNICEF deal marks a turning point in global health. It brings lifesaving malaria protection to millions more children. This is achieved through innovative financing, international partnership, and shared commitment. As malaria continues to threaten lives across sub-Saharan Africa, affordable vaccines offer a critical chance for survival, health, and hope.
